NeoGenomics to Present at the 4th Annual LD MICRO Growth Conference
FT. MYERS, Fla., Dec. 5, 2011 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM) announced today that it will present at the 4th Annual LD MICRO Growth Conference on Thursday, December 8, 2011 at 9:30 AM. The conference will showcase 101 small and microcap growth companies over two days, and is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, California. Senior executives of attending companies will make presentations to investors on their business strategy and outlook, and one-on-one meetings with interested parties will be arranged during the conference.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or [email protected] and from Zack's Investment Research at http://www.zacks.com or [email protected].
About LD MICRO:
LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor.
To learn more, please call 408-457-1042 or visit http://www.ldmicro.com
SOURCE NeoGenomics, Inc.
Share this article